SCHEMBL5312416

SCHEMBL5312416

NC(=O)NC(=O)Cc1nc2ccccc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.58
KMT2A Q03164 6/20 0.56
MEN1 O00255 5/20 0.56
ALDH1A1 P00352 2/20 0.56
HPGD P15428 2/20 0.56
UBE2T Q9NPD8 1/20 0.53
ASIC3 Q9UHC3 1/20 0.53
KDM4E B2RXH2 2/20 0.52
GAA P10253 1/20 0.52
POLB P06746 3/20 0.52
SMN1; SMN2 Q16637 4/20 0.51
NFKB1 P19838 1/20 0.51
CSNK1D P48730 1/20 0.51
NFKB2 Q00653 1/20 0.51
RELA Q04206 1/20 0.51
RAB9A P51151 3/20 0.50
NPC1 O15118 2/20 0.50
ALOX15 P16050 2/20 0.50
LMNA P02545 1/20 0.50
HTT P42858 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15617711 0.85 MAPT (0.57) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL77032 0.83 KMT2A (0.68) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL11343437 0.79 LMNA (0.71) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL27412092 0.79 HPGD (0.59) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL28469157 0.78 LMNA (0.59) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL12210188 0.78 CSNK1D (0.61) MAPTKMT2AMEN1HPGDKDM4E
SCHEMBL3684279 0.78 MAPT (0.60) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL1612659 0.78 SMN1; SMN2 (0.67) MAPTKMT2AMEN1ALDH1A1HPGD
SCHEMBL12210186 0.77 HPGD (0.73) MAPTALDH1A1HPGDKDM4EGAA
SCHEMBL18216848 0.77 CSNK1D (0.56) MAPTKMT2AMEN1ALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060194821-A1 Compounds inhibiting the aggregation of superoxide dismutase-1 THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2006-08-31 US claimed
EP-1853276-A2 COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 The Brighamn and Women's Hospital, Inc. (US) 2007-11-14 EP disclosed
US-20060194821-A1 Compounds inhibiting the aggregation of superoxide dismutase-1 THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2006-08-31 US disclosed
WO-2006089221-A2 COMPOUNDS INHIBITING THE AGGREGATION OF SUPEROXIDE DISMUTASE-1 THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) 2006-08-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060194821-A1 Compounds inhibiting the aggregation of superoxide dismutase-1 SOD1, SOD3, CAT MAPT 723/4885KMT2A 4043/4885MEN1 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.